Last reviewed · How we verify
NCT04575532: DeCODe
Detection of COVID-19 Decompensation
trial testing Use of the pinpointIQ solution (physIQ, Inc.) in Covid19 in 1,000 participants. Completed in 9 September 2021.
9 September 2021
Quick facts
| Lead sponsor | physIQ, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 5 October 2020 |
| Primary completion | 9 September 2021 |
| Estimated completion | 9 September 2021 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Use of the pinpointIQ solution (physIQ, Inc.)
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
physIQ, Inc.
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study we will be monitoring for patient events (emergency department admission, hospital admission, admission to an observation unit, or death) and evaluating the feasibility and utility of using pinpointIQ in the management of patients with COVID-19. Vital sign (physiology data) is collected to build a Covid Decompensation Index and contribute data to a Covid Digital Hub supported by the National Institutes of Health.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Wearable sensor derived decompensation index for continuous remote monitoring of COVID-19 diagnosed patients.
Richards DM, Tweardy MJ, Steinhubl SR, Chestek DW, et al · · 2021 · cited 14× · PMID 34750499 · DOI 10.1038/s41746-021-00527-z -
Personalized Analytics and a Wearable Biosensor Platform for Early Detection of COVID-19 Decompensation (DeCODe): Protocol for the Development of the COVID-19 Decompensation Index.
Larimer K, Wegerich S, Splan J, Chestek D, et al · · 2021 · cited 6× · PMID 33949966 · DOI 10.2196/27271 -
Evaluating an Advanced Practice Provider-Managed Coronavirus Disease 2019 Deterioration Program.
Kottler J, Khosla S, Recio V, Chestek D, et al · · 2023 · PMID 37693741 · DOI 10.1016/j.nurpra.2023.104754
Verify or expand the search:
- PubMed search for NCT04575532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other physIQ, Inc. trials
Trials by the same sponsor.
- NCT05237024 — (VIII): The Eight Study and Immunologic Response Sub-study · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04575532 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by physIQ, Inc.
- Last refreshed: 13 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04575532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing